臨床研究等提出・公開システム

Patient preferences of treatment for the patients suffering from muscle-invasive urothelial carcinoma of bladder following radical cystectomy in Japan (SNUGGLE) (SNUGGLE)

A Study to Evaluate Treatment Preferences for Japanese Participants With
Muscle-invasive Urothelial Carcinoma of the Bladder (SNUGGLE) (SNUGGLE)

Ito Hiroaki

Bristol-Myers Squibb K.K.

1-2-1 Otemachi Chiyoda-ku, Tokyo

hiroaki.ito@bms.com

Ito Hiroaki

Bristol-Myers Squibb K.K.

1-2-1 Otemachi Chiyoda-ku, Tokyo

+81-3-6705-7000

hiroaki.ito@bms.com

Not Recruiting

Mar. 15, 2023

Observational

1. Patients residing in Japan and able to speak/read Japanese for the interview/survey
2. Patients aged 18 years or more at the time of consent
3. Patients with a pathological diagnosis of MIBC (either of the following):
- ypT2-ypT4a or ypN+ MIBC, with prior neoadjuvant cisplatin chemotherapy and who underwent radical cystectomy
- pT3-pT4a or pN+ MIBC, without prior neoadjuvant cisplatin chemotherapy and who underwent radical cystectomy
4. Patients who have not received any treatment related to MIBC after radical cystectomy
5. Patients who are able and willing to provide written informed consent to participate in this study

1. Patient is determined by the physician as being unsuitable for the study
2. Patient has a confirmed diagnosis of other primary cancer(s) at the time of obtaining consent
3. Patient is currently participating in a MIBC clinical trial

Both

Muscle-invasie urothelial carcinoma

MIBC, patient preference,

D001749

1. To identify important treatment attributes for post-radical cystectomy (RC) treatment for patients with MIBC (Muscle-Invasive Bladder Cancer) in Japan.
2. To assess the relative importance of treatment attributes for post-RC treatment, such as disease-free survival, side effects, frequency of dosage etc.

To consider potential differences in treatment preferences amongst MIBC patients in Japan with differing demographic or clinical characteristics

+81-3-6416-1868

Dec. 21, 2022

Yes

It may be provided to overseas researchers.

none